These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 33694032)

  • 1. Time to re-engage psychiatric drug discovery by strengthening confidence in preclinical psychopharmacology.
    Tricklebank MD; Robbins TW; Simmons C; Wong EHF
    Psychopharmacology (Berl); 2021 Jun; 238(6):1417-1436. PubMed ID: 33694032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How do we re-engage the pharmaceutical industry in research on serotonin and psychiatric disorders?
    Green AR; Marsden CA
    ACS Chem Neurosci; 2013 Jan; 4(1):9-12. PubMed ID: 23336037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving Translational Relevance in Preclinical Psychopharmacology (iTRIPP).
    Bailey SJ; Bast T; Chaby L; Kinon BJ; Harte MK; Mead S; Moloney RD; Ragan I; Stanford SC; Tricklebank MD; Zervas M; Ajram LA
    J Psychopharmacol; 2023 Nov; 37(11):1051-1057. PubMed ID: 37522187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NIMH initiatives to facilitate collaborations among industry, academia, and government for the discovery and clinical testing of novel models and drugs for psychiatric disorders.
    Brady LS; Winsky L; Goodman W; Oliveri ME; Stover E
    Neuropsychopharmacology; 2009 Jan; 34(1):229-43. PubMed ID: 18800066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug discovery in psychopharmacology: from 2D models to cerebral organoids
.
    Rossetti AC; Koch P; Ladewig J
    Dialogues Clin Neurosci; 2019; 21(2):203-224. PubMed ID: 31636494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Back to the future of psychopharmacology: A perspective on animal models in drug discovery.
    Hendriksen H; Groenink L
    Eur J Pharmacol; 2015 Jul; 759():30-41. PubMed ID: 25814259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenges in developing drugs for pediatric CNS disorders: A focus on psychopharmacology.
    Grabb MC; Gobburu JVS
    Prog Neurobiol; 2017 May; 152():38-57. PubMed ID: 27216638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Learning from the past and looking to the future: Emerging perspectives for improving the treatment of psychiatric disorders.
    Millan MJ; Goodwin GM; Meyer-Lindenberg A; Ove Ögren S
    Eur Neuropsychopharmacol; 2015 May; 25(5):599-656. PubMed ID: 25836356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Evolving Role of Animal Models in the Discovery and Development of Novel Treatments for Psychiatric Disorders.
    Teal LB; Ingram SM; Bubser M; McClure E; Jones CK
    Adv Neurobiol; 2023; 30():37-99. PubMed ID: 36928846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Solving the crisis in psychopharmacological research: Cellular-membrane(s) pharmacology to the rescue?
    Drukarch B; Jacobs GE; Wilhelmus MMM
    Biomed Pharmacother; 2020 Oct; 130():110545. PubMed ID: 32731134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Challenges and opportunities for drug discovery in psychiatric disorders: the drug hunters' perspective.
    Wong EH; Yocca F; Smith MA; Lee CM
    Int J Neuropsychopharmacol; 2010 Oct; 13(9):1269-84. PubMed ID: 20716397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New approaches in psychiatric drug development.
    van der Doef TF; Zaragoza Domingo S; Jacobs GE; Drevets WC; Marston HM; Nathan PJ; Tome MB; Tamminga CA; van Gerven JMA; Kas MJH
    Eur Neuropsychopharmacol; 2018 Sep; 28(9):983-993. PubMed ID: 30056086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medications development for substance-use disorders: contextual influences (dis)incentivizing pharmaceutical-industry positioning.
    Janero DR
    Expert Opin Drug Discov; 2014 Nov; 9(11):1265-79. PubMed ID: 25162124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative Systems Pharmacology for Neuroscience Drug Discovery and Development: Current Status, Opportunities, and Challenges.
    Geerts H; Wikswo J; van der Graaf PH; Bai JPF; Gaiteri C; Bennett D; Swalley SE; Schuck E; Kaddurah-Daouk R; Tsaioun K; Pelleymounter M
    CPT Pharmacometrics Syst Pharmacol; 2020 Jan; 9(1):5-20. PubMed ID: 31674729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug targeting in psychiatric disorders - how to overcome the loss in translation?
    Khodosevich K; Dragicevic K; Howes O
    Nat Rev Drug Discov; 2024 Mar; 23(3):218-231. PubMed ID: 38114612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toward standardized usage of the word serendipity in the historiography of psychopharmacology.
    Baumeister AA; Hawkins MF; López-Muñoz F
    J Hist Neurosci; 2010 Jul; 19(3):253-70. PubMed ID: 20628954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How induced pluripotent stem cells are informing drug discovery in psychiatry.
    Sun Y; Dolmetsch RE
    Swiss Med Wkly; 2016; 146():w14241. PubMed ID: 26752334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correction to: Time to re-engage psychiatric drug discovery by strengthening confidence in preclinical psychopharmacology.
    Tricklebank MD; Robbins TW; Simmons C; Wong EHF
    Psychopharmacology (Berl); 2021 Jul; 238(7):2045. PubMed ID: 33999227
    [No Abstract]   [Full Text] [Related]  

  • 19. Paradoxes of US psychopharmacology practice in 2013: undertreatment of severe mental illness and overtreatment of minor psychiatric problems.
    de Leon J
    J Clin Psychopharmacol; 2014 Oct; 34(5):545-8. PubMed ID: 24781438
    [No Abstract]   [Full Text] [Related]  

  • 20. Ethical challenges in developing drugs for psychiatric disorders.
    Carrier F; Banayan D; Boley R; Karnik N
    Prog Neurobiol; 2017 May; 152():58-69. PubMed ID: 28268181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.